Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation
暂无分享，去创建一个
G. Mills | E. Winer | G. Hortobagyi | K. Do | V. Valero | L. Cantley | N. Lin | F. Meric-Bernstam | A. Sahin | A. González-Angulo | D. Hong | S. Piha-Paul | A. Eterovic | L. Doyle | M. Chávez-MacGregor | M. Maurer | V. Abramson | Yisheng Li | J. Litton | A. Akcakanat | Huiqin Chen | Y. Xing | G. Wulf | E. Tarco | A. Mahvash | Dianna Riall | N. Lin | A. K. Eterovic